FEROX STRATEGIES

Lobbying for FRESENIUS KABI USA LLC · Generic and biosimilar pharmaceutical manufacturer

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Illinois · House · Senate · $50,000.00 income · posted Jul 18, 2025

Lobbying activity 3

Health Issues

General healthcare issues related to generic and biosimilar industries.

Pharmacy

General patent issues related to generic and biosimilar industries.

Trade (domestic/foreign)

General issues related to trade.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.